Limited time offer
VetOne and KVP: Canine Cardiac Care
NT-proBNP Test. Available October 1st – November 30th, this exclusive offer supports canine congestive heart failure screening and management.
Effective, affordable canine CHF management
CaniBendan™ is indicated for the management of signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). CaniBendan™ can be used in concurrent CHF therapy (e.g., furosemide) as appropriate on a case-by-case basis.
Manufactured under Good Manufacturing Practices (GMP) with standardized potency, purity, and stability in every tablet, CaniBendan™ offers a trusted, proven option for managing chronic heart failure in your canine patients — exclusively through MWI Animal Health.
Simplify canine cardiac care without compromising on quality
First FDA-approved* generic alternative
Backed by MWI Animal Health and VetOne
Designed for easy administration
*Approved by FDA under ANADA # 200-728
Important Safety Information
CaniBendan™ (pimobendan chewable tablets) is indicated for use in dogs with clinical evidence of congestive heart failure. Do not administer in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. The safety of CaniBendan™ (pimobendan chewable tablets) has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than MMVD or DCM. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Please refer to the full Prescribing Information for complete safety details. CaniBendan™ (pimobendan chewable tablets) is for use in dogs only.